any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. known history of allergy to any component of the imp formulation. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry.

any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. known history of allergy to any component of the imp formulation. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry.